Siirry päänavigointiin Siirry hakuun Siirry pääsisältöön

Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics

  • International IPF Genetics Consortium
  • , Global Biobank Meta-Analysis Initiative (GBMI)
  • , Juulia J. Partanen*
  • , Paavo Häppölä
  • , Wei Zhou
  • , Arto A. Lehisto
  • , Mari Ainola
  • , Eva Sutinen
  • , Richard J. Allen
  • , Amy D. Stockwell
  • , Olivia C. Leavy
  • , Justin M. Oldham
  • , Beatriz Guillen-Guio
  • , Nancy J. Cox
  • , Jibril B. Hirbo
  • , David A. Schwartz
  • , Tasha E. Fingerlin
  • , Carlos Flores
  • , Imre Noth
  • , Brian L. Yaspan
  • R. Gisli Jenkins, Louise V. Wain, Samuli Ripatti, Matti Pirinen, Tarja Laitinen, Riitta Kaarteenaho, Marjukka Myllärniemi, Mark J. Daly, Jukka T. Koskela
*Tämän työn vastaava kirjoittaja

    Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

    58 Sitaatiot (Scopus)
    7 Lataukset (Pure)

    Abstrakti

    The research of rare and devastating orphan diseases, such as idiopathic pulmonary fibrosis (IPF) has been limited by the rarity of the disease itself. The prognosis is poor—the prevalence of IPF is only approximately four times the incidence, limiting the recruitment of patients to trials and studies of the underlying biology. Global biobanking efforts can dramatically alter the future of IPF research. We describe a large-scale meta-analysis of IPF, with 8,492 patients and 1,355,819 population controls from 13 biobanks around the globe. Finally, we combine this meta-analysis with the largest available meta-analysis of IPF, reaching 11,160 patients and 1,364,410 population controls. We identify seven novel genome-wide significant loci, only one of which would have been identified if the analysis had been limited to European ancestry individuals. We observe notable pleiotropy across IPF susceptibility and severe COVID-19 infection and note an unexplained sex-heterogeneity effect at the strongest IPF locus MUC5B.

    AlkuperäiskieliEnglanti
    Artikkeli100181
    JulkaisuCell Genomics
    Vuosikerta2
    Numero10
    DOI - pysyväislinkit
    TilaJulkaistu - 12 lokak. 2022
    OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

    Rahoitus

    This work was supported by the Doctoral Programme in Population Health, University of Helsinki (to J.J.P.); and The Finnish Medical Foundation (to J.J.P.); NHLBI (to J.O.); Wellcome Trust ( 221680/Z/20/Z to B.G.-G.); NHLBI (to D.A.S.), DoD (to D.A.S.); Spanish Ministry of Science and Innovation and Instituto de Salud Carlos III , co-financed by the European Regional Development Fund (ERDF) “A Way of Making Europe” from the European Union (EU) ( RTC-2017-6471-1 and PI20/00876 to C.F.); Cabildo Insular de Tenerife ( CGIEU0000219140 to C.F.); NIH (to I.N.), Medical Research Council – project grant (to R.G.J.); NIHR Research Professorship (to R.G.J.); GSK/Asthma + Lung UK Chair in Respiratory Research (C17-1) (to L.V.W.); Research Foundation of the Pulmonary Diseases HES (to R.K.); Jalmari and Rauha Ahokas Foundation (to R.K.); the Research Foundation of North Finland , Oulu, Finland, and a state subsidy of Oulu University Hospital (to R.K.); HUS State Research Funding (to M.M.); Academy of Finland (to J.T.K.). R.J.A. is an Action for Pulmonary Fibrosis Mike Bray Research Fellow. The work of the contributing biobanks for GBMI was supported by numerous grants from governmental and charitable bodies (see below). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Center; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR , or the Department of Health . The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health , and by NCI , NHGRI , NHLBI , NIDA , NIMH , and NINDS . The Graphical abstract was created with BioRender.com . BioBank Japan Project: The BioBank Japan Project was supported by the Tailor-Made Medical Treatment program of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), the Japan Agency for Medical Research and Development (AMED). S.N. was supported by Takeda Science Foundation. Y.O. was supported by JSPS KAKENHI ( 19H01021 and 20K21834 ), and AMED ( JP21km0405211 , JP21ek0109413 , JP21ek0410075 , JP21gm4010006 , and JP21km0405217 ), JST Moonshot R&D ( JPMJMS2021 and JPMJMS2024 ), Takeda Science Foundation , and Bioinformatics Initiative of Osaka University Graduate School of Medicine , Osaka University. BioMe - The Mount Sinai BioMe Biobank: The Mount Sinai BioMe Biobank has been supported by The Andrea and Charles Bronfman Philanthropies and in part by Federal funds from the NHLBI and NHGRI ( U01HG00638001 , U01HG007417 , and X01HL134588 ). We thank all participants in the Mount Sinai Biobank. We also thank all our recruiters who have assisted and continue to assist in data collection and management and are grateful for the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. BioVU: The BioVU projects at Vanderbilt University Medical Center are supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH -funded Shared Instrumentation Grant nos. S10OD017985 and S10RR025141 ; CTSA grants UL1TR002243 , UL1TR000445 , and UL1RR024975 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/. China Kadoorie Biobank collaborative group: The China Kadoorie Biobank collaborative group would like to thank the International Steering Committee: Junshi Chen, Zhengming Chen (PI), Robert Clarke, Rory Collins, Yu Guo, Liming Li (PI), Jun Lv, Richard Peto, Robin Walters, and Chen Wang. The China Kadoorie Biobank collaborative group would also like to thank the International Co-ordinating Centre, Oxford: Daniel Avery, Fiona Bragg, Derrick Bennett, Ruth Boxall, Ka Hung Chan, Yumei Chang, Yiping Chen, Zhengming Chen, Johnathan Clarke, Robert Clarke, Huaidong Du, Zammy Fairhurst-Hunter, Hannah Fry, Simon Gilbert, Alex Hacker, Parisa Hariri, Mike Hill, Michael Holmes, Pek Kei Im, Andri Iona, Maria Kakkoura, Christiana Kartsonaki, Rene Kerosi, Kuang Lin, Mohsen Mazidi, Iona Millwood, Qunhua Nie, Alfred Pozarickij, Paul Ryder, Sam Sansome, Dan Schmidt, Paul Sherliker, Rajani Sohoni, Becky Stevens, Iain Turnbull, Robin Walters, Lin Wang, Neil Wright, Ling Yang, Xiaoming Yang, and Pang Yao; and the National Co-ordinating Centre, Beijing: Yu Guo, Xiao Han, Can Hou, Chun Li, Chao Liu, Jun Lv, Pei Pei, and Canqing Yu. Regional coordinating centers would like to thank Guangxi Provincial CDC: Naying Chen, Duo Liu, and Zhenzhu Tang; Liuzhou CDC: Ningyu Chen, Qilian Jiang, Jian Lan, Mingqiang Li, Yun Liu, Fanwen Meng, Jinhuai Meng, Rong Pan, Yulu Qin, Ping Wang, Sisi Wang, Liuping Wei, and Liyuan Zhou; Gansu Provincial CDC: Caixia Dong, Pengfei Ge, Xiaolan Ren; Maiji CDC: Zhongxiao Li, Enke Mao, Tao Wang, Hui Zhang, and Xi Zhang; Hainan Provincial CDC: Jinyan Chen, Ximin Hu, and Xiaohuan Wang; Meilan CDC: Zhendong Guo, Huimei Li, Yilei Li, Min Weng, and Shukuan Wu; Heilongjiang Provincial CDC: Shichun Yan, Mingyuan Zou, and Xue Zhou; Nangang CDC: Ziyan Guo, Quan Kang, Yanjie Li, Bo Yu, and Qinai Xu; Henan Provincial CDC: Liang Chang, Lei Fan, Shixian Feng, Ding Zhang, and Gang Zhou; Huixian CDC: Yulian Gao, Tianyou He, Pan He, Chen Hu, Huarong Sun, and Xukui Zhang; Hunan Provincial CDC: Biyun Chen, Zhongxi Fu, Yuelong Huang, Huilin Liu, Qiaohua Xu, and Li Yin; Liuyang CDC: Huajun Long, Xin Xu, Hao Zhang, and Libo Zhang; Jiangsu Provincial CDC: Jian Su, Ran Tao, Ming Wu, Jie Yang, Jinyi Zhou, and Yonglin Zhou; Suzhou CDC: Yihe Hu, Yujie Hua, Jianrong Jin Fang Liu, Jingchao Liu, Yan Lu, Liangcai Ma, Aiyu Tang, and Jun Zhang; Qingdao CDC: Liang Cheng, Ranran Du, Ruqin Gao, Feifei Li, Shanpeng Li, Yongmei Liu, Feng Ning, Zengchang Pang, Xiaohui Sun, Xiaocao Tian, Shaojie Wang, Yaoming Zhai, and Hua Zhang; Licang CDC: Wei Hou, Silu Lv, and Junzheng Wang; Sichuan Provincial CDC: Xiaofang Chen, Xianping Wu, Ningmei Zhang, and Weiwei Zhou; Pengzhou CDC: Xiaofang Chen, Jianguo Li, Jiaqiu Liu, Guojin Luo, Qiang Sun, and Xunfu Zhong; Zhejiang Provincial CDC: Weiwei Gong, Ruying Hu, Hao Wang, Meng Wan, and Min Yu; and Tongxiang CDC: Lingli Chen, Qijun Gu, Dongxia Pan, Chunmei Wang, Kaixu Xie, and Xiaoyi Zhang. China Kadoorie Biobank gratefully acknowledges the participants, project staff, and the China National Centre for Disease Control and Prevention (CDC) and its regional offices. China’s National Health Insurance provides electronic linkage to all hospital treatment. Funding sources: baseline survey and first re-survey— Kadoorie Charitable Foundation , Hong Kong; long-term follow-up— UK Wellcome Trust ( 212946/Z/18/Z , 202922/Z/16/Z , 104085/Z/14/Z , 088158/Z/09/Z ), National Natural Science Foundation of China ( 91843302 ), National Key Research and Development Program of China ( 2016YFC 0900500 , 0900501 , 0900504 , 1303904 ); DNA extraction and genotyping – GlaxoSmithKline, UK Medical Research Council ( MC-PC-13049 , MC-PC-14135 ); core funding for the project to the Clinical Trial Service Unit and Epidemiological Studies Unit at Oxford University— British Heart Foundation ( CH/1996001/9454 ), UK Medical Research Council ( MC-UU-00017/1 , MC-UU-12026/2 , MC_U137686851 ), Cancer Research UK ( C16077/A29186 , C500/A16896 ). Estonian Biobank: Estonian Biobank research was supported by the European Union through Horizon 2020 research and innovation program under grant no. 810645 and through the European Regional Development Fund project no. MOBEC008, by the Estonian Research Council grant PUT ( PRG1291 , PRG687 , and PRG184 ) and by the European Union through the European Regional Development Fund project no. MOBERA21 (ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), project no. 2014-2020.4.01.15-0012, and project no. 2014-2020.4.01.16-0125. Estonian Biobank would like to acknowledge Dr. Tõnu Esko, Dr. Lili Milani, Dr. Reedik Mägi, Dr. Mari Nelis, and Dr. Andres Metspalu, all from the Institute of Genomics, University of Tartu, Tartu, Estonia. FinnGen: The FinnGen project is funded by two grants from Business Finland ( HUS 4685/31/2016 and UH 4386/31/2016 ) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd, Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc., and Novartis AG. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank ( www.auria.fi/biopankki ), THL Biobank ( www.thl.fi/biobank ), Helsinki Biobank ( www.helsinginbiopankki.fi ), Biobank Borealis of Northern Finland ( https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx ), Finnish Clinical Biobank Tampere ( www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere ), Biobank of Eastern Finland ( www.ita-suomenbiopankki.fi/en ), Central Finland Biobank ( www.ksshp.fi/fi-FI/Potilaalle/Biopankki ), Finnish Red Cross Blood Service Biobank ( www.veripalvelu.fi/verenluovutus/biopankkitoiminta ) and Terveystalo Biobank ( www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/ ). All Finnish Biobanks are members of BBMRI.fi infrastructure ( www.bbmri.fi ). Finnish Biobank Cooperative-FINBB ( https://finbb.fi/ ) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious services ( https://site.fingenious.fi/en/ ) managed by FINBB. Genes and Health: Genes & Health is/has recently been core-funded by Wellcome ( WT102627 , WT210561 ), the Medical Research Council (UK) ( M009017 ), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry Consortium of Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc., Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc., Takeda Development Centre Americas Inc. We thank Social Action for Health, Centre of The Cell, members of our Community Advisory Group, and staff who have recruited and collected data from volunteers. We thank the NIHR National Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry Centre (King’s College London), Wellcome Sanger Institute, and Broad Institute for sample processing, genotyping, sequencing, and variant annotation. We thank Barts Health NHS Trust, NHS Clinical Commissioning Groups (City and Hackney, Waltham Forest, Tower Hamlets, Newham, Redbridge, Havering, Barking, and Dagenham), East London NHS Foundation Trust, Bradford Teaching Hospitals NHS Foundation Trust, Public Health England (especially David Wyllie), Discovery Data Service/Endeavour Health Charitable Trust (especially David Stables)—for GDPR-compliant data sharing backed by individual written informed consent. Most of all, we thank all of the volunteers participating in Genes & Health. We would like to acknowledge the Genes & Health Research Team (in alphabetical order by surname): Shaheen Akhtar, Mohammad Anwar, Elena Arciero, Samina Ashraf, Gerome Breen, Raymond Chung, Charles J. Curtis, Maharun Chowdhury, Grainne Colligan, Panos Deloukas, Ceri Durham, Sarah Finer, Chris Griffiths, Qin Qin Huang, Matt Hurles, Karen A. Hunt, Shapna Hussain, Kamrul Islam, Ahsan Khan, Amara Khan, Cath Lavery, Sang Hyuck Lee, Robin Lerner, Daniel MacArthur, Bev MacLaughlin, Hilary Martin, Dan Mason, Shefa Miah, Bill Newman, Nishat Safa, Farah Tahmasebi, Richard C. Trembath, Bhavi Trivedi, David A. van Heel, and John Wright. The HUNT Study: A special thanks to all the HUNT participants for donating their time, samples, and information to help others. The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. The genetic investigations of the HUNT Study is a collaboration between researchers from the K.G. Jebsen Center for Genetic Epidemiology, NTNU and the University of Michigan Medical School and the University of Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norway. We want to thank clinicians and other employees at Nord-Trøndelag Hospital Trust for their support and for contributing to data collection in this research project. We also acknowledge HUNT-MI Leadership: Kristian Hveem, Cristen Willer, Oddgeir Lingaas Holmen, Mike Boehnke, Goncalo Abecasis, Bjorn Olav Åsvold, and Ben Brumpton; Scientific Advisory Committee: Ele Zeggini, Mark Daly, and Bjørn Pasternak; HUNT Research Centre: Jørn Søberg Fenstad, Anne Jorunn Vikdal, and Marit Næss; HUNT Cloud: Oddgeir Lingaas Holmen, Sandor Zeestraten, and Tom Erik Røberg; data applications and registry linkages: Maiken E. Gabrielsen and Anne Heidi Skogholt; low-pass whole sequencing genome bioinformatics and statistical analysis: He Zhang, Hyun Min Kang, and Jin Chen; array genotyping: Sten Even Erlandsen and Vidar Beisvåg; GWAS bioinformatics, QC, imputation, and statistical analysis: Wei Zhou, Jonas Nielsen, Lars Fritsche, Hyun Min Kang, Oddgeir Holmen, Ben Brumpton, and Laurent Thomas; CNV calling: Ellen Schmidt and Ryan Mills; and statistical methods development for analyzing HUNT data: Wei Zhou and Shawn Lee. The K.G. Jebsen Centre for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen. The genotyping in HUNT was financed by the National Institutes of Health; University of Michigan; the Research Council of Norway; Stiftelsen Kristian Gerhard Jebsen; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St Olav’s hospital and the Faculty of Medicine and Health Sciences, NTNU. Other G.D.S., T.R.G., and J.Z. are supported by a grant from the Medical Research Council for the Integrative Epidemiology Unit at the University of Bristol MC_UU_00011/1 & 4. J.Z. is supported by the Academy of Medical Sciences (AMS) Springboard Award, the Wellcome Trust, the Government Department of Business, Energy and Industrial Strategy (BEIS), the British Heart Foundation and Diabetes UK (SBF006\1117). J.Z. is funded by the Vice-Chancellor Fellowship from the University of Bristol. W.Z. was supported by the National Human Genome Research Institute of the National Institutes of Health under award no. T32HG010464 . A.S. and B.L.Y. are full-time employees of Genentech with stock and stock options in Roche. D.A.S. is the founder and chief scientific officer of Eleven P15, a company focused on the early diagnosis and treatment of IPF. T.E.F. is a consultant to Eleven P15. R.G.J. has received research funding from Astra Zeneca, Biogen, Galecto, GlaxoSmithKline, RedX, and Pliant; consulting fees from Bristol Myers Squibb, Daewoong, Veracyte, Resolution Therapeutics, RedX, and Pliant; payment for lectures, presentations, speakers bureaus, manuscript writing or educational events from Chiesi, Roche, PatientMPower, and AstraZeneca; payment for Participation on a Data Safety Monitoring Board or Advisory Board from Boehringer Ingelheim, Galapagos, and Vicore, had a Leadership or fiduciary role in other board, society, committee or advocacy group (unpaid) in NuMedii and Action for Pulmonary Fibrosis; and is a trustee for Action for Pulmonary Fibrosis. L.V.W. has received research funding from GSK and Orion Pharma and consultancy for Galapagos. M.J.D. is a founder of Maze Therapeutics. J.T.K. and M.J.D. are members of the Pfizer Finland FinnGen Advisory Board.

    Julkaisufoorumi-taso

    • Jufo-taso 0

    Sormenjälki

    Sukella tutkimusaiheisiin 'Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

    Siteeraa tätä